Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Certara services see widespread use in H1 2018
September 2018
SHARING OPTIONS:

PRINCETON, N.J.—According to Certara, 95 percent of the novel drugs approved by the FDA in the first half of the year were supported by the company’s software or services. Certara notes that the “FDA has been a leader promoting modeling and simulation as an integral part of drug development and review, highlighting it specifically in the 21st Century Cures Act, PDUFA VI and GDUFA II.”
 
“Our mission is to revolutionize the drug development paradigm by leveraging modern quantitative approaches such as modeling and simulation and real-world evidence solutions to optimize R&D productivity, commercial value and patient outcomes. These technologies’ positive impact is evident in the accelerated development cycles for these approved drugs and the innovation adoption by the FDA,” Dr. Edmundo Muniz, CEO of Certara, said in a press release.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
478 Bay Street, Suite A213
Midland, Ontario, Canada L4R 1K9
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.